title: Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells.
abstract: The neurotoxicity of antipsychotic (AP) drugs seems to be linked with neurological side effects like extrapyramidal symptoms (EPS). On the other hand, neuroprotective effects can mitigate or slow the progressive degenerative structural changes in the brain leading to improved outcome of schizophrenia. First and second-generation antipsychotics may differ in their neurotoxic and neuroprotective properties. The aim of this study was to compare the neurotoxic/neuroprotective activity of haloperidol, a first-generation antipsychotic, and risperidone, a second-generation one, with paliperidone, a relatively new second-generation antipsychotic, in SK-N-SH cells. Haloperidol, risperidone and paliperidone (10, 50, 100 μM) were administered, either alone or in combination with dopamine (100 μM), to human neuroblastoma SK-N-SH. We examined the effects of the drugs on cell viability (measured by alamarBlue®), caspase-3 activity (measured by fluorimetric assay) and cell death (by measuring the externalization of phosphatidylserine). Haloperidol significantly decreased cell viability and increased caspase-3 activity and cell death. Risperidone and paliperidone did not affect cell viability or cell death. Both second-generation APs decreased caspase-3 activity, especially paliperidone. In cells treated with dopamine in combination with antipsychotics, only paliperidone (10 μM) induced a slight improvement in cell viability. While haloperidol potentiated the dopamine-induced increase in caspase-3 activity, risperidone and paliperidone reduced this effect. The results indicate that haloperidol induces apoptosis, whereas risperidone and paliperidone may afford protection against it. Of the APs tested, paliperidone always showed the strongest neuroprotective effect. The different antipsychotic effects on survival and cell death might be related to differences in their capacity to induce EPS.
authors: Department Pathological Anatomy, Pharmacology and Microbiology, University of Barcelona, Spain.
authors: Patricia
authors: P
authors: Gassó
authors: Sergi
authors: S
authors: Mas
authors: Oriol
authors: O
authors: Molina
authors: Miquel
authors: M
authors: Bernardo
authors: Amalia
authors: A
authors: Lafuente
authors: Eduard
authors: E
authors: Parellada
mesh_terms: D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006220:Haloperidol / Q000627:therapeutic use / Q000633:toxicity*; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use / Q000633:toxicity*; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D000068882:Paliperidone Palmitate; D011743:Pyrimidines / Q000627:therapeutic use / Q000633:toxicity*; D018967:Risperidone / Q000627:therapeutic use / Q000633:toxicity*
chemical_list: D007555:Isoxazoles; D018696:Neuroprotective Agents; D011743:Pyrimidines; D006220:Haloperidol; D018967:Risperidone; D000068882:Paliperidone Palmitate